A stroke is an emergency. Call 911 if stroke symptoms are happening now; time matters, even if symptoms fade. The American Stroke Association says even one suspected symptom warrants an immediate call.
Semax for stroke has been studied in Russia, but the evidence does not establish it as a replacement for emergency treatment or rehabilitation, therapy for recovering everyday skills. Small Russian clinical studies and rat experiments explain the interest. They do not establish how much benefit a person can expect, or whether a different pharmacy-prepared medicine produces the same results.
Semax for stroke: where the evidence comes from
Semax is a synthetic peptide, a laboratory-made short chain of protein building blocks. Russian clinical publications describe it as an addition to stroke care. Most of the studies discussed here concern ischemic stroke, meaning a blocked blood vessel cuts off blood to part of the brain.
That distinction matters because a stroke caused by bleeding is a different condition. These studies cannot answer treatment questions for every kind of stroke. The broader guide to what Semax is used for separates its other clinical uses. The account of who developed Semax follows its origins.
In Gusev and colleagues' 1997 study, published in Zhurnal Nevrologii i Psikhiatrii, 30 people received Semax alongside intensive stroke care. Another 80 received conventional care. The groups had strokes described as similar in severity and location.
Researchers used clinical rating scales and EEG, a recording of the brain's electrical activity. They also measured electrical responses to sensory stimulation. The authors reported faster improvement in some neurological problems, particularly movement.
The English abstract does not describe random assignment or blinding, where participants or assessors do not know which treatment was given. It provides no numerical size of the recovery difference. The finding is an early signal, rather than a dependable estimate of benefit.
Those results concern Semax alongside hospital treatment. They do not establish results for Semax/Selank, the separate combination named on the product card.
What the other Russian studies measured
Two later papers ask different questions. Their findings should not be combined into one claim that Semax improves recovery at every stage. The summaries below draw on the papers' PubMed abstracts, rather than their Russian full texts.
| Study | People and design described | What was measured |
|---|---|---|
| Miasoedova and colleagues, 1999 | A retrospective comparison, meaning researchers looked back at treatment data; the abstract gives no participant count | Biological markers related to inflammation after acute stroke |
| Gusev and colleagues, 2018 | 110 people in earlier or later rehabilitation, divided into groups receiving or not receiving Semax | A blood protein, muscle performance and independence in everyday activities |
Both appeared in Zhurnal Nevrologii i Psikhiatrii. The 1999 abstract describes changes in inflammation-related measurements. It does not describe random assignment or blinding, and it does not supply a numerical recovery result.
The 2018 study involved adults averaging about 58 years old. Its earlier rehabilitation group began around three months after stroke; the later group began around seven months. The Russian abstract describes five months of observation.
Researchers measured BDNF, a protein involved in nerve-cell maintenance and signaling. They also assessed strength and the Barthel Index, a score for everyday tasks such as eating and dressing.
The authors reported higher BDNF levels and better recovery scores with Semax. Neither abstract describes random assignment or blinding. Rehabilitation timing also affected the findings, so the results cannot cleanly separate the peptide's contribution from other differences between groups.
A blood protein change is not the same as being able to walk independently. The study measured both kinds of information, but its abstract gives no numerical between-group improvement to use as a personal forecast.
What rat neuroprotection means
Neuroprotection means trying to limit injury to nerve cells. It describes a research goal, not proof that a medicine protects a person's brain.
In Filippenkov and colleagues' 2020 study in Genes, researchers temporarily blocked a brain artery in rats, then restored blood flow. They measured gene activity afterward: which genetic instructions the cells were using. Semax was associated with lower activity in inflammation-related genes and higher activity in genes involved in communication between nerve cells.
That experiment offers a possible explanation for further study. It does not measure a person's speech, walking or long-term independence. The guide to how Semax works covers the wider biological research.
Adding Selank introduces another ingredient. A rat experiment with Semax alone does not test the combination, and neither does a clinical study of Semax alone.
Has a Western stroke trial tested Semax?
As of October 1, 2026, the day this article was written, a PubMed search identified no Western randomized stroke trial of Semax. A ClinicalTrials.gov search through its public API returned zero records for Semax. That registry result describes its records, not every study conducted worldwide.
It would be too broad to say Semax has never been studied in a randomized stroke trial. A 2011 Russian clinical recommendations document describes 160 people assigned to Semax or placebo, a comparison preparation without the active ingredient. It calls the study randomized and double-blind, meaning neither patients nor the people measuring outcomes knew the assignment.
The document describes four groups of 40 and follow-up through 30 days. Outcomes included neurological rating scales, everyday function and death. This is a Russian recommendations document reporting a study, rather than independent Western replication.
The useful distinction is between a reported Russian randomized study and a modern, independently replicated trial that could guide expectations elsewhere. One cannot stand in for the other.
What the July FDA vote changed
As of October 1, 2026, the day this article was written, the July 24 FDA advisory recommendation is relevant to Semax's U.S. status. The official FDA recording shows eight votes in favor, five against and one abstention for listing Semax free base, the form without an added salt.
The vote concerned the 503A Bulks List, an ingredient list for certain medicines compounded for individual prescriptions. It did not approve a finished drug or establish a stroke treatment. Semax's FDA history explains the separate regulatory record.
FDA's May 11, 2026 review identifies no approved U.S. drug containing Semax. Semax is not FDA-approved, and a compounded Semax/Selank preparation is different from an FDA-approved product: the formulation offered here is not FDA-approved. The Semax / Selank blend is offered through Promise as a compounded injectable vial after a licensed provider reviews your request. A licensed provider may still prescribe — that decision is between you and your doctor.
The committee recommendation does not fill the clinical evidence gaps. It also does not make the combination equivalent to the single-ingredient preparations studied in Russia.
What a care conversation needs to settle
Recovery care remains centered on the stroke team and rehabilitation. The American Stroke Association's rehabilitation guide describes therapy tailored to movement, communication and daily activities. Semax evidence does not justify replacing that care.
A provider reviewing a peptide request needs the stroke type, timing, current difficulties and complete medication list. The exact preparation matters too. Follow-up needs a clear goal, such as a measured daily activity, rather than a general impression of brain support.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The prescriber sets any dose and follow-up plan. An accountable clinical relationship can address uncertainty; it cannot turn a small study into a promised recovery.
